Back to results
US 10,947,308 B2Granted
Composition for treatment of disorders
AssigneeCrescendo Biologics Limited
InventorsKaren Bannister, Ulla Lashmar, Daniel Pettit, Thomas Sandal
Life of this patent
Estimating the term…
Abstract
The invention relates to stable and non-aggregating compositions comprising an IL-17A binding molecule, in particular a single domain antibody. Such compositions are useful for topical administration in the treatment of disease, for example skin disease or asthma.
Claims18
A composition comprising
- a) an effective amount of at least one single variable heavy chain domain antibody capable of binding human IL-17A,
- b) 75-150 mM Tris/glycine, 80-125 mM L-arginine/glutamic acid, 4.5-29.5% propylene glycol and 7.5-10% sorbitol at a pH of 8.0,
- 100 mM Tris/glycine, 125 mM L-arginine/glutamic acid, 6% propylene glycol and 5% trehalose dihydrate at a pH of 8.0 or
- 100 mM Tris/glycine, 150 mM L-arginine/glutamic acid, 7% propylene glycol at a pH of 8.0;
- wherein said single variable heavy chain domain antibody comprises a CDR1 having SEQ ID NO:
- 2, a CDR2 having SEQ ID NO:
- 3, and a CDR3 having SEQ ID NO:
- 4.
5 more elements
A freeze or spray dried composition comprising
- a) an effective amount of at least one single variable heavy chain domain antibody comprising a VH domain capable of binding human IL-17A and
- b) 75-100 mM Tris/glycine, 80-125 mM L-arginine/glutamic acid, 4.5-29.5% propylene glycol and 7.5-10% sorbitol at a pH of 8.0,
- 100 mM Tris/glycine, 125 mM L-arginine/glutamic acid, 6% propylene glycol and 5% trehalose dihydrate at a pH of 8.0 or
- 100 mM Tris/glycine, 150 mM L-arginine/glutamic acid, 7% propylene glycol at a pH of 8.0;
- wherein said single variable heavy chain domain antibody comprises a CDR1 having SEQ ID NO:
- 2, a CDR2 having SEQ ID NO:
- 3, and a CDR3 having SEQ ID NO:
- 4.
5 more elements
Dependencies are inferred from the claim text.